Clinical Trial

Salivary Apelin, Chemerin, Ghrelin, and Lipocalin-2 Levels in Diabetic Patients With Periodontitis

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 14, 2026 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This observational cross-sectional study will evaluate salivary apelin, chemerin, ghrelin, and lipocalin-2 levels in individuals with different periodontal and systemic conditions. Participants will be divided into four groups according to periodontal status and the presence or absence of type 2 diabetes mellitus. Clinical periodontal measurements and unstimulated saliva samples will be obtained before periodontal treatment. Salivary biomarker levels will be measured using enzyme-linked immunosorbent assay kits. The study aims to determine whether salivary apelin, chemerin, ghrelin, and lipocalin-2 levels are associated with periodontitis, type 2 diabetes mellitus, and periodontal clinical parameters.
Trial Details
NCT Number NCT07703345
Lead Sponsor Necmettin Erbakan University
Conditions Periodontitis, Type 2 Diabetes Mellitus (T2DM)
Enrollment 88 participants
Start Date 2026-07-01
Primary Completion 2026-08-01 (estimated)
Study Completion 2026-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-14